Ipsen Secures EU Nod for Ojemda, First Targeted Therapy for Pediatric Low-Grade Glioma
Event summary
- Ipsen's Ojemda (tovorafenib) approved in the EU for relapsed/refractory pediatric low-grade glioma, regardless of BRAF alteration.
- Approval based on Phase II FIREFLY-1 study showing 71% overall response rate and manageable safety profile.
- First medicine to undergo EU's new Joint Clinical Assessment (JCA) process under the 2025 HTA Regulation.
- Ipsen licensed ex-U.S. rights to tovorafenib from Day One Biopharmaceuticals in 2024.
The big picture
The approval highlights the persistent innovation gap in pediatric therapeutics, where less than 10% of new medicine approvals over the past five years have focused on pediatric diseases. Ipsen's success with Ojemda positions it as a leader in targeted therapies for rare pediatric cancers, though the company must navigate the complexities of the EU's evolving regulatory landscape. The approval also underscores the strategic importance of Ipsen's partnership with Day One Biopharmaceuticals, which provided the foundational asset for this breakthrough.
What we're watching
- Market Access Dynamics
- The pace at which EU member states implement the new JCA process and integrate Ojemda into national healthcare systems.
- Commercial Execution
- Whether Ipsen can effectively launch Ojemda across Europe, given the rare disease and pediatric focus.
- Pipeline Progression
- The potential expansion of tovorafenib's use into front-line treatment for pediatric low-grade glioma.
Related topics